Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ADIABullishCorporate Developmentsnews

Medium materiality6/10

Adia Med Advances Toward NASDAQ Uplisting with Regulatory Milestones

Jul 13, 2026, 9:04 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Uplist to NASDAQ is a major liquidity catalyst for microcaps; historically, uplist-related announcements have produced price upside, though execution risk and biotech timing can cap upside until clinical milestones materialize.

AI summary

What happened, with direct paths to the underlying reporting

Adia Med Inc. reports rapid progress since its 2024 leadership shift, advancing regulatory milestones and a plan to uplist to NASDAQ. Highlights include FDA biologics registration, IRB approvals for autism and other studies, revenue growth to $637k in the first nine months of 2025, and the launch of Adia Life to broaden distribution.

Adia Med highlights rapid milestones since the 2024 leadership transition.
2025 revenue reached $637,145 nine months; driven by biologics and clinics.
FDA biologics registration completed; ASD/CKD IRB approvals in 2026.
Form 10 effective; NASDAQ uplist planned as thresholds near.
Adia Life expands nationwide distribution, focusing Adia Labs on R&D.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.